Vycor Medical INC: management transactions · United States · SEC (Form 4)

About Vycor Medical INC

Vycor Medical Inc. (ticker: VYCO) is a U.S.-based healthcare company headquartered in Boca Raton, Florida, United States. It is currently quoted on the OTCQB rather than the NYSE or NASDAQ, but it remains relevant for investors following U.S. medical-device microcaps and SEC filing activity, including insider transactions reported on Form 4. The company was formed in 2005 as Vycor Medical LLC and later converted into a Delaware corporation in 2007. From inception, Vycor has pursued a highly specialized strategy focused on neurosurgical access and neuro-therapeutic solutions. Its business is organized around two operating units. The first, Vycor Medical, commercializes the ViewSite™ Brain Access System (VBAS), a disposable cranial access platform designed for neurosurgery. The second, NovaVision®, is a development-stage business offering therapy programs intended to help patients recover visual function after stroke or brain injury. Vycor’s market position is that of a niche specialty device company rather than a broad-based medtech platform. In this segment, clinical credibility matters as much as commercial execution. The company has emphasized a growing body of peer-reviewed publications supporting VBAS, which can be important for surgeon adoption, hospital procurement discussions, and credibility in a highly technical market. At the same time, the company remains small and capital-sensitive, with performance tied to product adoption, geographic expansion, and continued progress in development-stage initiatives. From a geographic standpoint, Vycor’s footprint is still modest, but recent disclosures indicate that growth has been increasingly driven by international markets, while sales in the United States also continue to expand. That suggests the company is gradually building a broader commercial reach beyond its home market, though it is not yet a large global medtech franchise. Recent company updates point to improving operating trends. In 2025, Vycor reported higher revenues for the Vycor Medical division, with growth largely coming from international markets. It also reported improved operating profitability versus the prior year. The company’s year-end 2025 release continued that pattern, showing further revenue growth and a return to positive operating income at the division level. Those developments are notable for a small-cap medical device issuer because they suggest better operational leverage even as NovaVision remains in development. For investors, Vycor Medical is best viewed as a focused U.S. healthcare microcap with asymmetric potential: a narrow product portfolio, a specialized clinical niche, and meaningful execution risk. The stock’s characteristics are consistent with a company where regulatory, commercialization, and evidence-generation milestones can matter disproportionately to valuation.